Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138733 · ClinicalTrials.gov registry record · Phase 3
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
A Phase 3 study, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 3
- Development phase
- 390
- Enrollment target
NCT03138733: Completed Phase 3 study, sponsored by Basilea Pharmaceutica.
NCT03138733 is a Phase 3 study that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 390 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03138733, a Phase 3 study, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
Primary Outcome
Comparison of overall success rates in the mITT population Overall success at PTE for the mITT population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)
Interventions
- DRUG Daptomycin
- DRUG Ceftobiprole medocaril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2018-08-26 |
| Est. Completion | 2022-03-11 |
| Phase | Phase 3 |
What the finished NCT03138733 record still lists
NCT03138733 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (49% lower).
The record links to 0 conditions, and to 2 interventions - of which Daptomycin is the first listed.
NCT03138733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03138733 about?
NCT03138733 is a clinical study titled "Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia". The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).
What is the current status of trial NCT03138733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 390 participants. The study started on 2018-08-26. Estimated completion is 2022-03-11.
What interventions are being tested in trial NCT03138733?
The interventions under investigation include: Daptomycin (DRUG), Ceftobiprole medocaril (DRUG).
Who is sponsoring clinical trial NCT03138733?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03138733's enrollment target sits among peer trials
390 968th of 2000 higher than 1,029 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI